Abstract
Objective:
To determine whether adjuvant transforming growth factor-β (TGF-β) inhibition with pirfenidone (PFD) can mitigate ureteral wall scarring and related complications in a rat model of upper urinary tract ablation with irreversible electroporation (IRE).
Methods:
Transmural ablation of the ureter was performed with IRE in 24 rats. Post-IRE, animals were randomly assigned to receive PFD or no drug, followed by euthanasia at 2-, 5-, or 10-days. The complete urinary tract was extracted, and the dimensions of kidney and ureter were measured. Immunohistochemistry was performed to quantify collagen deposition, α-smooth muscle actin (α-SMA) (myofibroblasts in ureter and kidney) and TGF-β (ureter only).
Results:
Enlargement of the kidney and ureteral dilatation were apparent during gross necropsy of rats from both cohorts. The changes in anatomical measurements were significantly reduced in rats receiving PFD at Day 5 and 10 (p = 0.02 and 0.04, respectively). Collagen levels in the ureters gradually increased in rats from both cohorts at Day 2 and 5, but started to reduce by Day 10 in rats receiving PFD when compared with no treatment (p = 0.04). Myofibroblast levels and TGF-β staining in the ureters was lower in rats receiving PFD on Day 5 and 10, respectively (p < 0.01). Collagen levels and myofibroblast staining of the kidneys from rats receiving PFD was significantly lower than control on Days 5 and 10.
Conclusion:
Adjuvant PFD can reduce myofibroblast activity and ureteral fibrosis at the site of IRE ablation, enabling safe soft tissue ablation adjacent or involving the upper urinary tract.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
